Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 2 1

Status

Active not recruiting 3

Sponsor Class

INDUSTRY 2OTHER 1

Study Type

Interventional 3

Sponsor

Cancer Type

NET 1Gynecologic 1Genitourinary 1Endocrine 1

Conditions

Recurrence 1Neuroendocrine Tumors 1Kidney Neoplasms 1Endometrial Neoplasms 1Carcinoma, Renal Cell 1

Interventions

pembrolizumab 95Specimen Handling 79Magnetic Resonance Spectroscopy 70Carboplatin 59Cisplatin 56Biopsy 56Nivolumab 51Radiotherapy 47Cyclophosphamide 44Paclitaxel 43Radiation 36durvalumab 33Gemcitabine 31olaparib 30Dexamethasone 30Etoposide 29Doxorubicin 28atezolizumab 26Taxes 25Rituximab 25Docetaxel 25Ipilimumab 24Bevacizumab 24Vincristine 23Lenalidomide 23Pemetrexed 22Cytarabine 22X-Rays 21Radiotherapy, Intensity-Modulated 21Prednisone 21

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Has results × Everolimus × 90 days × Clear all
NCT04195750 2026-05-14

A Study of Belzutifan (MK-6482) Versus Everolimus in Participants With Advanced Renal Cell Carcinoma (MK-6482-005)

Merck Sharp & Dohme LLC

Phase 3 Active not recruiting
755 enrolled 28 charts 1 FDA
Genitourinary

Carcinoma, Renal Cell, Kidney Neoplasms

NCT01068249 2026-04-30

Letrozole and RAD001 With Advanced or Recurrent Endometrial Cancer

M.D. Anderson Cancer Center

Phase 2 Active not recruiting
42 enrolled 11 charts
Gynecologic

Recurrence, Endometrial Neoplasms

NCT03049189 2026-04-06

COMPETE

ITM Solucin GmbH

Phase 3 Active not recruiting
324 enrolled 15 charts
EndocrineNET

Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡